Efficacy and Safety of Moxonidine in Indian Patients

This study has been completed.

Sponsored by:	Solvay Pharmaceuticals
Information provided by:	Solvay Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00160277

Purpose

The purpose of this study is to demonstrate efficacy and safety of Moxonidine in Indian subjects.

Condition	Intervention	Phase
Hypertension	Drug: Moxonidine	Phase III

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Moxonidine

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Open Label, Multi-Center, Force-Titration Study to Evaluate the Efficacy and Safety of Moxonidine in Ambulatory Subjects With Essential Hypertension

Further study details as provided by Solvay Pharmaceuticals:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	100
Study Start Date:	July 2005

Eligibility

Criteria

Inclusion Criteria:

Hypertension

Exclusion Criteria:

Severe concomitant diseases, CHF, secondary hypertension, severe hypertension, significant hepatic disease, unstable angina

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00160277

Locations

India
Site 1
Jubillee Hills Hyderabad, India
Site 2
Mangalore, India
Site 3
New Delhi, India

Sponsors and Collaborators

Solvay Pharmaceuticals

Investigators

Study Director:

Global Clinical Director Solvay

Solvay Pharmaceuticals

More Information

Study ID Numbers:	S220.3.124
Study First Received:	September 9, 2005
Last Updated:	September 6, 2007
ClinicalTrials.gov Identifier:	NCT00160277
Health Authority:	India: Indian Council of Medical Research

Keywords provided by Solvay Pharmaceuticals:

Efficacy and safety of moxonidine in Indian hypertensives

Study placed in the following topic categories:

Moxonidine
Vascular Diseases
Essential hypertension
Hypertension

Additional relevant MeSH terms:

Therapeutic Uses
Cardiovascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009